The Reporting Persons acquired the shares of Common Stock reported herein for investment purposes. Dr. Aghazadeh serves as a member of the board of directors of the Issuer. The Issuer and certain of its stockholders, including Avoro Life Sciences and Avoro Ventures Fund, are parties to the Amended and Restated Investors' Rights Agreement, dated March 17, 2021, among the Issuer and certain of its stockholders (the "IRA"). Pursuant to the IRA, holders of Registrable Securities (as defined in the IRA), including the Funds, are entitled to certain registration rights with respect to shares of Common Stock issued upon conversion of the Issuer's preferred stock, with such rights terminating upon the earliest to occur of (i) the closing of a Deemed Liquidation Event (as defined in the IRA), (ii) such time as Rule 144 under the Securities Act of 1933, as amended, is available for the sale of all of a holder's shares without limitation during a three-month period without registration and (iii) the third anniversary of the closing of the IPO. The IRA also contains customary lock-up provisions pursuant to which the Funds have agreed not to sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of, any Common Stock or other securities of the Issuer held immediately prior to the effective date of the registration statement IPO for a period of 180 days following the effective date of the registration statement for the IPO. The foregoing description of the IRA does not purport to be complete and is qualified in its entirety by reference to the full text of the IRA, the form of which is filed as Exhibit 99.1 hereto and incorporated herein by reference. In connection with the IPO, holders of the requisite majorities of Registrable Securities under the IRA, including the Funds, delivered a Waiver of Registration Rights and Related Notice waiving (i) all registration rights of Registrable Securities with respect to the IPO and (ii) all demand registration rights provided for in the IRA until the date that is 180 days after the effective date of the registration statement for the IPO. Also in connection with the IPO, each of Avoro Life Sciences and Avoro Ventures Fund entered into a lock-up agreement, dated April 10, 2026, with certain financial institution counterparties, as representatives of the several underwriters of the IPO (each, a "Lock-Up Agreement"), pursuant to which each Fund agreed, subject to the terms and conditions set forth therein, not to offer, sell, pledge or otherwise transfer or dispose of, or engage in any hedging or similar transaction with respect to, any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock, whether owned at the time or thereafter acquired, and not to cause or direct any of its affiliates to do so, in each case, for a period of 180 days after the date of the final prospectus for the IPO, which is dated July 23, 2026. The restrictions are subject to specified exceptions, including sales of shares of Common Stock acquired from the underwriters in the IPO or acquired in open market transactions after the closing of the IPO. By Notice of Extension to the Funds, dated June 29, 2026, the Issuer informed the Funds it had extended the termination date of each Lock-Up Agreement to September 28, 2026 (unless earlier terminated pursuant to the agreements' terms). The foregoing description of the Lock-Up Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of a form of the Lock-Up Agreements, a copy of which is filed as Exhibit 99.2 hereto and incorporated herein by reference. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, the outcome of any discussions referenced herein, actions taken by the board of directors, price levels of the Common Stock, other investment opportunities available to the Reporting Persons, market conditions and general economic and industry conditions, the Reporting Persons may take such actions with respect to their investment in the Issuer as they deem appropriate, including, without limitation, purchasing additional shares of Common Stock or other financial instruments related to the Issuer or selling some or all of their holdings, subject to the restrictions described in Item 6 and applicable law, and, alone or with others, engaging in communications with the board of directors and management of the Issuer, other stockholders of the Issuer and other persons regarding the Issuer. Dr. Aghazadeh may receive compensation from the Issuer for his service as a director, including equity awards, in accordance with the Issuer's non-employee director compensation policy. Except as set forth herein, the Reporting Persons do not have, as of the date of this Schedule 13D, any present plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to formulate plans or proposals, and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of Schedule 13D, and any other actions, as they may determine.